BR112018010066A2 - agente estimulante do receptor 5-hidroxitriptamina 1b para intensificar potencial de enxerto in vivo - Google Patents

agente estimulante do receptor 5-hidroxitriptamina 1b para intensificar potencial de enxerto in vivo

Info

Publication number
BR112018010066A2
BR112018010066A2 BR112018010066A BR112018010066A BR112018010066A2 BR 112018010066 A2 BR112018010066 A2 BR 112018010066A2 BR 112018010066 A BR112018010066 A BR 112018010066A BR 112018010066 A BR112018010066 A BR 112018010066A BR 112018010066 A2 BR112018010066 A2 BR 112018010066A2
Authority
BR
Brazil
Prior art keywords
hydroxytryptamine
enhance
stimulating agent
receptor stimulating
vivo graft
Prior art date
Application number
BR112018010066A
Other languages
English (en)
Other versions
BR112018010066A8 (pt
Inventor
Bruno Chretien Fabrice
Rocheteau Pierre
Gaillard Raphael
Original Assignee
Centre Hospitalier Sainte Anne Paris
Pasteur Institut
Univ Paris Descartes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Hospitalier Sainte Anne Paris, Pasteur Institut, Univ Paris Descartes filed Critical Centre Hospitalier Sainte Anne Paris
Publication of BR112018010066A2 publication Critical patent/BR112018010066A2/pt
Publication of BR112018010066A8 publication Critical patent/BR112018010066A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
    • A61L27/3687—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment characterised by the use of chemical agents in the treatment, e.g. specific enzymes, detergents, capping agents, crosslinkers, anticalcification agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/499—Spiro-condensed pyrazines or piperazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/02—Materials or treatment for tissue regeneration for reconstruction of bones; weight-bearing implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/30—Materials or treatment for tissue regeneration for muscle reconstruction

Abstract

a presente invenção refere-se ao campo da medicina regenerativa e, mais particularmente, à melhoria do potencial de enxerto in vivo de material biológico a ser administrado a um indivíduo em necessidade do mesmo.
BR112018010066A 2015-11-20 2016-07-15 Agente estimulante do receptor 5-hidroxitriptamina 1b para intensificar potencial de enxerto in vivo BR112018010066A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562257816P 2015-11-20 2015-11-20
EP16305446 2016-04-15
PCT/EP2016/066965 WO2017084774A1 (en) 2015-11-20 2016-07-15 5-hydroxytryptamine 1b receptor-stimulating agent for enhancing in vivo engraftment potential

Publications (2)

Publication Number Publication Date
BR112018010066A2 true BR112018010066A2 (pt) 2018-11-13
BR112018010066A8 BR112018010066A8 (pt) 2022-11-22

Family

ID=55806270

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018010066A BR112018010066A8 (pt) 2015-11-20 2016-07-15 Agente estimulante do receptor 5-hidroxitriptamina 1b para intensificar potencial de enxerto in vivo

Country Status (10)

Country Link
US (2) US11013830B2 (pt)
EP (1) EP3377051B1 (pt)
JP (1) JP6847946B2 (pt)
KR (1) KR20180102071A (pt)
CN (1) CN108697670A (pt)
AU (1) AU2016356504B2 (pt)
BR (1) BR112018010066A8 (pt)
CA (1) CA3005396A1 (pt)
MX (1) MX2018006226A (pt)
WO (1) WO2017084774A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2992161A1 (en) 2015-07-17 2017-01-26 Institut Pasteur 5-hydroxytryptamine 1b receptor-stimulating agent for use as a promoter of satellite cells self-renewal and/or differentiation
US11013830B2 (en) 2015-11-20 2021-05-25 Institut Pasteur 5-hydroxytryptamine 1B receptor-stimulating agent for enhancing in vivo engraftment potential
CN108727393B (zh) * 2018-08-06 2019-10-29 广东东阳光药业有限公司 苯基二氮杂双环衍生物及其用途
EP3659672A1 (en) * 2018-11-28 2020-06-03 Institut Gustave Roussy Combined use of selective serotonin reuptake inhibitors and hematopoietic growth factors for treating hematopoietic diseases
CN109851573B (zh) * 2018-12-07 2022-11-18 华南理工大学 一种沃替西汀氨基酸酰胺类化合物及其制备方法和应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA81749C2 (uk) 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
WO2007044005A1 (en) 2005-10-06 2007-04-19 Tubular Fabricators Industry, Inc. Replaceable hand grip
SI2044043T2 (sl) * 2006-06-16 2021-04-30 H. Lundbeck A/S 1-2(-2,4-dimetilfenilsulfanil)-fenil)piperazin hidrobromid kot spojina s kombinirano aktivnostjo ponovnega privzema serotonina, 5-ht3 in 5-ht1a za zdravljenje kognitivne motnje
CN103664847A (zh) * 2006-06-22 2014-03-26 雷蒙特亚特特拉维夫大学有限公司 作为具外周系统限制活性药物的五羟色胺再摄取抑制剂
US20100092454A1 (en) 2006-12-22 2010-04-15 Enrico De Vivo novel use of antidepressant compounds and related compositions
GB0907350D0 (en) 2009-04-29 2009-06-10 Myotec Therapeutics Ltd Methods
RU2611376C2 (ru) * 2010-10-15 2017-02-21 Контера Фарма Апс Фармацевтическая композиция для лечения, профилактики или облегчения двигательных расстройств и ее применение
WO2012174537A2 (en) 2011-06-16 2012-12-20 President And Fellows Of Harvard College Small molecule screening for mouse satellite cell proliferation
GB201120259D0 (en) 2011-11-24 2012-01-04 Univ Gent Allogeneic immune response control
US20140179706A1 (en) * 2012-12-21 2014-06-26 Map Pharmaceuticals, Inc. Fluoroergoline derivatives and uses thereof
US20160101093A1 (en) 2013-05-21 2016-04-14 Jason B. Wynberg Methods for the treatment of premature ejaculation
CA2992161A1 (en) 2015-07-17 2017-01-26 Institut Pasteur 5-hydroxytryptamine 1b receptor-stimulating agent for use as a promoter of satellite cells self-renewal and/or differentiation
WO2017063771A1 (en) 2015-10-14 2017-04-20 Institut Pasteur 5-hydroxytryptamine 1b receptor-stimulating agent for the treatment of myocardial infarction
US11013830B2 (en) 2015-11-20 2021-05-25 Institut Pasteur 5-hydroxytryptamine 1B receptor-stimulating agent for enhancing in vivo engraftment potential
BR112019000706A8 (pt) 2016-07-15 2022-12-06 Pasteur Institut Agente de estímulo do receptor 1b de 5-hidroxitriptamina para reparo de pele e/ou cabelo

Also Published As

Publication number Publication date
JP6847946B2 (ja) 2021-03-24
US20180326121A1 (en) 2018-11-15
MX2018006226A (es) 2018-11-09
CN108697670A (zh) 2018-10-23
AU2016356504A1 (en) 2018-06-21
AU2016356504B2 (en) 2022-01-20
WO2017084774A1 (en) 2017-05-26
CA3005396A1 (en) 2017-05-26
EP3377051A1 (en) 2018-09-26
US20210330863A1 (en) 2021-10-28
US11013830B2 (en) 2021-05-25
EP3377051B1 (en) 2022-03-30
JP2018534325A (ja) 2018-11-22
KR20180102071A (ko) 2018-09-14
BR112018010066A8 (pt) 2022-11-22
AU2016356504A8 (en) 2018-06-28

Similar Documents

Publication Publication Date Title
PH12017501342A1 (en) Glycan therapeutics and related methods thereof
PH12018500586A1 (en) Farnesoid x receptor agonists and uses thereof
BR112018010066A2 (pt) agente estimulante do receptor 5-hidroxitriptamina 1b para intensificar potencial de enxerto in vivo
BR112018003984A2 (pt) anticorpos
PH12019502058A1 (en) Farnesoid x receptor agonists and uses thereof
MX2017015574A (es) Inhibidores de tirosina quinasa de bruton.
MX2020010412A (es) Inhibidores de tirosina quinasa de bruton.
EA201692477A1 (ru) Композиции и способы применения для лечения метаболических расстройств
CL2018000739A1 (es) Terapia adjuntiva con 25-hidroxi vitamina d y artículos de la misma.
TW201613919A (en) Inhibitors of Bruton&#39;s tyrosine kinase
EA201890272A1 (ru) Axl-специфические конъюгаты антитело-лекарственное средство для лечения рака
MX2023000796A (es) Composicion farmaceutica, metodos para tratamiento y sus usos.
BR112015004875A2 (pt) formulações de anticorpo e seus usos
BR112017016503A2 (pt) conjugado de fármaco de citotoxicidade-ligante, método de preparação para o mesmo, e aplicação para o mesmo
BR112015025025A2 (pt) composições terapêuticas e usos das mesmas
CY1123366T1 (el) Παραγωγα 8-αμινο-2-οξο-1,3-διαζα-σπειρο-[4.5]-δeκανιου
BR112018015367A2 (pt) carreadores oromucosais de nanofibra para tratamento terapêutico
BR112017019413A2 (pt) combinação de agente bactericida com um agente alcalinizante lisossomotrópico para o tratamento de uma infecção bacteriana
BR112015010039A2 (pt) tratamento de câncer com pomalidomida em um individuo com disfunção renal
EA201890457A1 (ru) Комбинации антитела против ox40 и модулятора tlr4 и их применение
MA40535A (fr) Imagerie et thérapie d&#39;une inflammation et d&#39;une infection ciblant hsp90
MX2016002408A (es) Metodos para el tratamiento de trastornos oticos pediatricos.
CY1122882T1 (el) Παραγωγα 3-(καρβοξυαιθυλ)-8-αμινο-2-οξο-1,3-διαζα-σπειρο-[4.5]-δεκανιου
EA201792571A1 (ru) Терапевтическое применение l-4-хлорокинуренина
BR112017025553A2 (pt) composição de vacina, e kit

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B25A Requested transfer of rights approved

Owner name: INSTITUT PASTEUR (FR) ; CENTRE HOSPITALIER SAINTE ANNE PARIS (FR) ; UNIVERSITE DE PARIS (FR)

B25D Requested change of name of applicant approved

Owner name: INSTITUT PASTEUR (FR) ; CENTRE HOSPITALIER SAINTE ANNE PARIS (FR) ; UNIVERSITE PARIS CITE (FR)

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]